Major histocompatibility complex class II region confers susceptibility to Staphylococcus aureus arthritis.
The importance of the MHC class II region for the development of septic arthritis was studied in a murine model of haematogenously induced Staphylococcus aureus arthritis. In the first experiment MHC class II deficient mice (A beta-/-) and their heterozygous (A beta+/-) littermates were intravenously inoculated with a single dose of toxic shock syndrome toxin-1 producing S. aureus LS-1 strain. The results demonstrate that the expression of class II MHC molecules increases the prevalence and severity of arthritis. To analyse the impact of MHC class II haplotypes on the disease onset and progression the authors used congenic C3H.NB, C3H.Q and C3H/HeJ mice in the second set of experiments. The results show that C3H/HeJ mice developed the highest frequency and the most severe course of arthritis compared with C3H.NB and C3H.Q animals. Immunohistochemical analysis of arthritic joints revealed equal number of macrophages, CD4+ and CD8+ lymphocytes in the inflamed synovia in all the congenic mice. In contrast, the number of MHC class II expressing cells was higher in the arthritic joints of C3H/HeJ mice compared with the congenic strains (P < 0.001). Furthermore, serum levels of proarthrtitogenic cytokines, such as tumour necrosis factor and interleukin-6 were higher in C3H/HeJ group. This study indicates that MHC class II expression is necessary for the development of S. aureus arthritis in mice and that different MHC class II haplotypes confer varying susceptibility for development of joint inflammation induced by staphylococci.
Abdelnour
A
A
Department of Rheumatology, University of Göteborg, Sweden.
Zhao
Y X
YX
Holmdahl
R
R
Tarkowski
A
A
D000818:Animals; D000941:Antigens / Q000008:administration & dosage / Q000494:pharmacology; D001170:Arthritis, Infectious / Q000209:etiology* / Q000235:genetics / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis; D004198:Disease Susceptibility; D000949:Histocompatibility Antigens Class II / Q000235:genetics*; D007150:Immunohistochemistry; D007275:Injections, Intravenous; D007719:Knee Joint; D008213:Lymphocyte Activation; D051379:Mice; D008809:Mice, Inbred C3H; D008817:Mice, Mutant Strains; D008934:Mitogens / Q000008:administration & dosage / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000209:etiology* / Q000235:genetics / Q000276:immunology*; D018089:Superantigens / Q000008:administration & dosage / Q000494:pharmacology
D000941:Antigens; D016207:Cytokines; D000949:Histocompatibility Antigens Class II; D008934:Mitogens; D018089:Superantigens